JNJ Johnson & Johnson
Company Analysis
Latest News
Johnson & Johnson hits 52-week high, UBS raises target to $320
Johnson & Johnson shares reached a new 52-week high on Wednesday. UBS increased its price target for the stock to $320 from $280. The share price rose...
Johnson & Johnson Offsets Stelara Losses With New Drug Sales
Johnson & Johnson navigates the loss of exclusivity for its blockbuster immunology drug, Stelara. Stelara sales declined by $913 million in the second quarter...
🟢 Johnson & Johnson is trading 3.13% up today as healthcare stocks gain
Johnson & Johnson is trading at 3.13% up now at $279.69 after healthcare-sector strength. • Healthcare stocks gained 1.37% during regular trading. • No new...
Johnson & Johnson's Stelara Wins FDA Approval for Pediatric Ulcerative Colitis
The U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's Stelara (ustekinumab) injection for moderately to severely active ulcerative colitis...
Robert Olstein's fund exits Johnson & Johnson stake
Value investor Robert Olstein of Olstein Capital Management has completely sold off his firm's stake in Johnson & Johnson, according to a recent quarterly...
Johnson & Johnson's Psoriasis Pill Icotyde Gains Approval in China
China's drug regulator approved Johnson & Johnson's oral medication, Icotyde (icotrokinra), for moderate-to-severe plaque psoriasis. The approval offers a new...
Johnson & Johnson wins FDA approval for IMAAVY, first-ever rare blood treatment
Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval for IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia (wAIHA)....
Farallon Capital more than doubles its Johnson & Johnson stake
Farallon Capital Management significantly increased its stake in Johnson & Johnson by over 175%, bringing its total holdings to 408,000 shares. According to...
Johnson & Johnson Secures EU Approval for TECVAYLI, Targeting Second-Line Myeloma
The European Commission approved an expanded indication for Johnson & Johnson’s TECVAYLI (teclistamab) in combination with daratumumab. This treatment targets...
Trump taps Heidi Overton for FDA, following 3,000 staff departures
President Donald Trump expects to nominate Heidi Overton as the next Food and Drug Administration (FDA) commissioner. Overton currently serves as a top aide at...
🟢 Johnson & Johnson is trading 3.12% up today as investors rotate toward defensive healthcare stocks
Johnson & Johnson is trading 3.12% up now at $270.56, as investors rotate toward defensive healthcare stocks. - The healthcare sector is up 1.59%, while the...
J&J’s DePuy Synthes expands in India, weighing $20B sale or spinoff
DePuy Synthes, Johnson & Johnson’s orthopedics division, is establishing a new Global Capability Centre in Bangalore, India. The hub will focus on innovation...
Johnson & Johnson Announces Retirement of EVP of Innovative Medicine, Names Successor
Johnson & Johnson announced that Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, will retire effective September 1,...
🔴 Johnson & Johnson is trading 3.6% down today on profit-taking and sector weakness
Johnson & Johnson is trading 3.6% down at $255.87 as the stock faces profit-taking after recent gains pushed shares toward record levels. • The decline comes...
🟢 Johnson & Johnson is trading 3.1% up today after $5.5B talc settlement announcement
Johnson & Johnson is trading 3.1% up today at $273.75 after announcing a $5.5 billion agreement to resolve outstanding ovarian talc litigation, removing a...
JNJ Reaches $5.5 Billion Agreement to Resolve Ovarian Talc Litigation
Johnson & Johnson announced it has reached an agreement to resolve the outstanding ovarian talc litigation. The comprehensive resolution is designed to address...
Johnson & Johnson's Oral Psoriasis Drug 'Icotyde' Recommended for EU Approval
A key committee of the European Medicines Agency (EMA) recommended marketing authorization for Johnson & Johnson's new drug, Icotyde. The Committee for...
Johnson & Johnson Myeloma Combo Cuts Progression Risk 89% in Phase 3
Johnson & Johnson reported positive topline results from the Phase 3 MonumenTAL-6 study for multiple myeloma. The trial evaluated a dual-antigen regimen...
Judge Casts Doubt on Evidence in 69,000 J&J Talc Lawsuits
A U.S. federal judge has raised significant doubts about the scientific evidence underpinning approximately 69,000 lawsuits alleging Johnson & Johnson's talc...
J&J Wins FDA Clearance for OTTAVA, Entering Competitive Surgical Robotics Market
Johnson & Johnson received U.S. Food and Drug Administration (FDA) De Novo authorization for its OTTAVA Robotic Surgical System. The system performs various...